Outlook Therapeutics updates on Type A meeting with FDA for ONS-5010; no definitive resolution

Outlook Therapeutics, Inc.

Type A meeting held with FDA to discuss December 30, 2025 Complete Response Letter for ONS-5010 BLA.
FDA had requested confirmatory evidence of effectiveness; no safety concerns identified by FDA.
Company expects continued discussions to clarify agency views on confirmatory evidence.
ONS-5010 met primary endpoints in Phase 3 NORSE TWO trial; NORSE EIGHT provided confirmatory efficacy/safety data.
If approved, ONS-5010 would be first FDA-approved ophthalmic bevacizumab with US manufacturing supply chain.

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-26-024189
form_type: 8-K
ticker: OTLK
cik: 0001649989
company_name: Outlook Therapeutics, Inc.
filed_at: 2026-03-05T23:59:59+00:00
discovered_at: 2026-05-14T18:02:35.757768+00:00
generated_at: 2026-05-15T19:42:06.204496+00:00
sec_items: ["8.01", "9.01"]
event_type: regulatory
sentiment: neutral
materiality_score: 0.55
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-26-024189
json_url: https://secwatch.observer/filing/0001104659-26-024189.json
markdown_url: https://secwatch.observer/filing/0001104659-26-024189.md
text_url: https://secwatch.observer/filing/0001104659-26-024189.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1649989/000110465926024189/0001104659-26-024189-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1649989/000110465926024189/tm268164d1_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001104659-26-024189

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.